Responding to a recent request for input from the field, the AHA yesterday urged the Center for Medicare and Medicaid Innovation to balance the risk and reward in its alternative payment models “in a way that reflects the significant investments required to launch and maintain APM participation.” It also urged CMMI to “factor implementation periods into any future APMs and reduce mid-model changes to the greatest degree possible,” noting that many AHA members “have indicated they need one to two years to make all the necessary operational, administrative and clinical adjustments to succeed in models.” In addition, AHA urged CMMI to ensure participants “have timely, usable data about their attributed populations,” and “support providers’ ability to deliver accessible, equitable care to patients.” 

Headline
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 editorial criticizing the 340B Drug…
Headline
The Centers for Medicare & Medicaid Services has released its fiscal year 2025 Program for Evaluating Payment Patterns Electronic Reports, or PEPPERs, for…
Headline
The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a functional third-party…
Headline
The Centers for Medicare & Medicaid Services has begun collecting private payor rate data through its Fee-for-Service Data Collection System Clinical Lab…
Headline
The Food and Drug Administration April 28 announced its plan to advance the implementation of real-time clinical trials, which invite participants to supply…
Headline
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…